-
1
المؤلفون: Naoyuki Nogami, Shunta Mori, Yumi Asakura, Daijiro Harada, Kenji Takata, Takayuki Ohno, Satoko Moriki, Toshiyuki Kozuki, Yoshika Takechi
المصدر: Anticancer Research. 39:4987-4993
مصطلحات موضوعية: Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Combination therapy, Pleural effusion, Docetaxel, Antibodies, Monoclonal, Humanized, Gastroenterology, Ramucirumab, Immunomodulation, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Odds Ratio, medicine, Humans, Adverse effect, Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Pneumonitis, business.industry, Hazard ratio, Antibodies, Monoclonal, Drug Synergism, Combination chemotherapy, General Medicine, Middle Aged, medicine.disease, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dfe4c0209694e2283f5f00e043dd0de
https://doi.org/10.21873/anticanres.13688 -
2
المؤلفون: Y. Asakura, K. Takata, T. Ono, Toshiyuki Kozuki, Satoko Moriki, Yoshika Takechi, Naoyuki Nogami, Daijiro Harada, S. Mori
المصدر: Annals of Oncology. 30:v645
مصطلحات موضوعية: medicine.medical_specialty, Combination therapy, business.industry, Immune checkpoint inhibitors, Salvage treatment, Confidential interval, Combination chemotherapy, Hematology, Ramucirumab, Oncology, Docetaxel, Internal medicine, Tumor regression, Medicine, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ea2cc46fb87e47ae778368725b3d869e
https://doi.org/10.1093/annonc/mdz260.088 -
3
المؤلفون: Yoshika Takechi, Y. Kogure, Tomohiro Ikuta, Naoyuki Nogami, Daijiro Harada, Toshiyuki Kozuki, Satoko Moriki
المصدر: Annals of Oncology. 28:ix107
مصطلحات موضوعية: medicine.medical_specialty, Oncology, Exacerbation, business.industry, Medicine, Hematology, Nivolumab, business, Intensive care medicine, Outcome (game theory)
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::fe6f13b66816d1088236cfff88f0b7ab
https://doi.org/10.1093/annonc/mdx621.056